Images |
Sources |
Experiment + Assay |
Phenotypes |
Human Diseases |
|
Fig.4 N
Gouignard N et al. (2016)
|
Xla Wt + dse MO
NF15 (in situ hybridization)
|
|
Ehlers-Danlos syndrome
|
|
Fig.5 B
Gouignard N et al. (2016)
|
Xla Wt + dse MO
NF20 (in situ hybridization)
|
|
Ehlers-Danlos syndrome
|
|
Fig.5 I
Gouignard N et al. (2016)
|
Xla Wt + dse MO
NF26 (in situ hybridization)
|
|
Ehlers-Danlos syndrome
|
|
Fig 2. b
Melchionda M et al. (2016)
|
Xla Wt + CAX MO
NF23-24 (in situ hybridization)
|
|
|
|
Fig 2. b
Melchionda M et al. (2016)
|
Xla Wt + CAX MO
NF23-24 (in situ hybridization)
|
|
|
|
fig.S4.b
Zhao Y et al. (2016)
|
Xla Wt + efhc1 MO
NF25 (in situ hybridization)
|
|
|
|
fig.6.a
Macrì S et al. (2016)
|
Xla Wt + hmga2 + msx1
NF16 (in situ hybridization)
|
|
|
|
fig.6.c
Macrì S et al. (2016)
|
Xla Wt + hmga2 + snai2
NF16 (in situ hybridization)
|
|
|
|
fig.5.b
Macrì S et al. (2016)
|
Xla Wt + hmga2 MO
NF16 (in situ hybridization)
|
|
|
|
fig.S6.b
Macrì S et al. (2016)
|
Xla Wt + hmga2 MO
NF22-25 (in situ hybridization)
|
|
|